|
Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
|
17 March 2020 |
|
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
|
03 March 2020 |
|
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
|
12 February 2020 |
|
Sandoz completes acquisition of Aspen's Japanese operations, strengthening its position in world's third largest market for generics and off-patent medicines
|
31 January 2020 |
|
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
|
10 December 2019 |
|
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa
|
19 November 2019 |
|
Novartis Cosentyx® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
|
04 November 2019 |
|
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
|
16 October 2019 |
|
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
|
02 October 2019 |
|
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
|
05 September 2019 |